RT Journal Article
SR Electronic
T1 Clinical value of lung clearance index (LCI) among patients with cystic fibrosis
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P1218
VO 44
IS Suppl 58
A1 Elpis Hatziagorou
A1 Vasiliki Avramidou
A1 Asterios Kampouras
A1 Fotis Kirvasillis
A1 John Tsanakas
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P1218.abstract
AB Background:The lung clearance index (LCI) is a promising endpoint for use in cystic fibrosis (CF) clinical trials, but correlations with validated clinical endpoints have not yet been established.Objective: To assess the ability of LCI to predict a positive sputum culture and a pulmonary exacerbation among patients with CF.Method: LCI, forced expiratory volume in 1 s (FEV1), sputum cultures and pulmonary exacerbations (PE) over a three-year period were prospectively recorded in 62 patients aged 5–25 years. Over the three- year period 622 measurements of LCI were recorded. Baseline LCI was assessed and was correlated with a positive sputum culture and a pulmonary exacerbation. The ability of LCI to assess a pulmonary exacerbation was assessed.Results: Mean age of the study population was 9.9 years, mean baseline FEV1 was 97.8% predicted (±19), while mean LCI was 9.6 (±2.9). Patients with negative sputum cultures had significantly lower mean LCI than patients with pseudomonas aeruginosa (N=199), (ΔLCI=-2.37, p<0.001), lower LCI than patients with stenotrophomonas maltophilia (n=26), (ΔLCI=-1.45, p=0.117) and comparable mean LCI to patients with staphylococcus aureus (n=141), (ΔLCI=-0.35, p=1).Mean LCI measured among patients being on exacerbation was significantly higher than mean baseline LCI (mean LCI= 11.13 and 9.6, respectively, p=0.013). A mean difference of 2.8 from baseline LCI was found to predict pulmonary exacerbation among the patient population (p<0.001).Conclusions: Lung clearance index is a valuable marker to evaluate longitudinally lung disease among patients with CF.